Cover Image

Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safely

Junko H Ohyashiki,1 Kazushige Ohtsuki,1 Izuru Mizoguchi,2 Takayuki Yoshimoto,2 Seiichiro Katagiri,3 Tomohiro Umezu,1,4 Kazuma Ohyashiki3,4 1Department of Molecular Oncology, Institute of Medical Science, 2Department of Immunoregulation, Institute of Medical Science, 3Department of Hematolog...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ohyashiki JH (Author), Ohtsuki K (Author), Mizoguchi I (Author), Yoshimoto T (Author), Katagiri S (Author), Umezu T (Author), Ohyashiki K (Author)
Format:	Book
Published:	Dove Medical Press, 2014-08-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia
by: Alexandra Rodrigues Alves, et al.

A novel non-invasive monitoring assay of 5-azacitidine efficacy using global DNA methylation of peripheral blood in myelodysplastic syndrome
by: Asano M, et al.
Published: (2019)

Chromatin Regulation by HP1γ Contributes to Survival of 5-Azacytidine-Resistant Cells
by: Satoshi Imanishi, et al.
Published: (2018)

The C allele of <it>JAK2 </it>rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population
by: Ohyashiki Junko H, et al.
Published: (2012)

The Undetected
by: Smith, George O. (George Oliver), 1911-1981; Finlay, Virgil, 1914-1971 [Illustrator]

Imatinib-induced extensive hyperpigmentation in a case of chronic myeloid leukemia
by: Pradeep Balasubramanian, et al.
Published: (2015)

Imatinib associated discoid lupus erythematosus in a patient with chronic myeloid leukemia
by: Priya Sarlashkar, BS, et al.
Published: (2024)

Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib
by: Ronan Swords, et al.
Published: (2009)

Hypoxia-induced paclitaxel resistance in cervical cancer modulated by miR-100 targeting of USP15
by: Hirotaka Nishi, et al.
Published: (2023)

Estimating undetected Ebola spillovers.
by: Emma E Glennon, et al.
Published: (2019)

Hyperpigmentation of the hard palate mucosa in a patient with chronic myeloid leukaemia taking imatinib
by: Gian Paolo Bombeccari, et al.
Published: (2017)

Multiple eruptive dermatofibromas secondary to imatinib mesylate in a patient with chronic myeloid leukemia
by: Francisco J Lira-Valero, et al.
Published: (2021)

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec®, Gleevec™)
by: Martin Henkes, et al.
Published: (2008)

Constitutional DNA Polymorphisms Associated with the Plasma Imatinib Concentration in Chronic Myeloid Leukemia Patients
by: Heriberto Bruzzoni-Giovanelli, et al.
Published: (2024)

Spectrum of BCR-ABL mutations in Azerbaijanian imatinib-resistant patients with chronic myeloid leukemia
by: Aypara Hasanova, et al.
Published: (2023)

Undetected Severe Fetal Myelosuppression following Administration of High-Dose Cytarabine for Acute Myeloid Leukemia: Is More Frequent Surveillance Necessary?
by: Jessica Parrott, et al.
Published: (2017)

Quantification of undetectable plasma HIV RNA
by: N. Margot, et al.
Published: (2017)

Undetected hypothyroidism and unexpected anesthetic complications
by: P Sudha, et al.
Published: (2012)

Imatinib- and Nilotinib-Induced Lichenoid Eruption in Chronic Myeloid Leukemia: A Rare Case Report
by: Meenakshi Sachdeva, et al.
Published: (2023)

Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia
by: Hyacinthe Johnson-Ansah, et al.
Published: (2022)

Real‐world efficacy and safety outcomes of imatinib treatment in patients with chronic myeloid leukemia: An Australian experience
by: Josephine A. Adattini, et al.
Published: (2022)

Comparative study for the efficacy, safety and quality of life in patients of chronic myeloid leukemia treated with Imatinib or Hydroxyurea
by: Parveen Jain, et al.
Published: (2013)

Effects of Trough Concentration and Solute Carrier Polymorphisms on Imatinib Efficacy in Chinese Patients with Chronic Myeloid Leukemia
by: Qing Wang, et al.
Published: (2020)

Imatinib therapy of chronic myeloid leukemia significantly reduces carnitine cell intake, resulting in adverse events
by: Pavel Burda, et al.
Published: (2024)

Panoramic radiographs for identifying individuals with undetected osteoporosis
by: Akira Taguchi
Published: (2009)

Disseminated neuroendocrine neoplasm with undetected primary tumor
by: Frederico Becker Ribeiro, et al.
Published: (2012)

Imatinib induced lichen planus
by: R Sudha, et al.
Published: (2011)

Overexpression of MicroRNA-148b-3p stimulates osteogenesis of human bone marrow-derived mesenchymal stem cells: the role of MicroRNA-148b-3p in osteogenesis
by: Samaneh Mollazadeh, et al.
Published: (2019)

Bartonella henselae endocarditis in Laos - 'the unsought will go undetected'.
by: Sayaphet Rattanavong, et al.
Published: (2014)

Factors Influencing the Steady-State Plasma Concentration of Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors and Chronic Myeloid Leukemia
by: Yan Chen, et al.
Published: (2020)

Application of physiologically based pharmacokinetic modeling to understand real‐world outcomes in patients receiving imatinib for chronic myeloid leukemia
by: Josephine A. Adattini, et al.
Published: (2023)

The effect of imatinib and nilotinib on blood calcium and blood potassium levels in chronic myeloid leukemia patient: a literature review
by: Muhammad Darwin Prenggono, et al.
Published: (2021)

Study of correlation between imatinib mesylate plasma levels and hematological profile of patients undergoing treatment for chronic myeloid leukemia
by: Emanuelle S. Dal Ponte, et al.
Published: (2017)

Status and analysis of undetected plague cases in Yunnan Province, China
by: Chao Su, et al.
Published: (2024)

HIV knowledge and its correlation with the Undetectable = Untransmittable slogan in Brazil
by: Rayane C. Ferreira, et al.
Published: (2022)

Polymorphisms in Drug Transporter and Metabolism Genes Associated with Resistance to Imatinib in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis
by: Ana Marcela Arrieta Gómez, et al.
Published: (2023)

Assessment of fibrosis and vascularization of bone marrow stroma of chronic myeloid Leukemia patients treated with imatinib mesylate and their relationship with the cytogenetic response
by: Caroline Regina de Jesus, et al.
Published: (2011)

"Journey of Uncertainties:" Nature of Transitioning among Persons Living with Undetectable HIV
by: Rudolf Cymorr Kirby Martinez
Published: (2020)

Modeling undetected poliovirus circulation following the 2022 outbreak in the United States
by: Dominika A. Kalkowska, et al.
Published: (2024)

From Undetectable Equals Untransmittable (U=U) to Breastfeeding: Is the Jump Short?
by: Tullio Prestileo, et al.
Published: (2022)